#### Check for updates

#### OPEN ACCESS

EDITED BY Lenin Pavón, National Institute of Psychiatry Ramon de la Fuente Muñiz (INPRFM), Mexico

#### REVIEWED BY

Oscar Medina-Contreras, Mexico Children's Hospital, Mexico Mauricio Castanon-Arreola, Universidad Autónoma de la Ciudad de México, Mexico

### \*CORRESPONDENCE

Xiaorong Yang yangxiaorong@sdu.edu.cn Xiuli Zuo zuoxiuli@sdu.edu.cn

#### RECEIVED 27 July 2023

ACCEPTED 29 September 2023 PUBLISHED 13 October 2023

#### CITATION

Yang X, Yang L, Zhang T, Zhang H, Chen H and Zuo X (2023) Causal atlas between inflammatory bowel disease and mental disorders: a bi-directional 2-sample Mendelian randomization study. *Front. Immunol.* 14:1267834. doi: 10.3389/fimmu.2023.1267834

#### COPYRIGHT

© 2023 Yang, Yang, Zhang, Zhang, Chen and Zuo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Causal atlas between inflammatory bowel disease and mental disorders: a bi-directional 2-sample Mendelian randomization study

# Xiaorong Yang<sup>1,2,3,4</sup>\*, Lejin Yang<sup>5</sup>, Tongchao Zhang<sup>2</sup>, Hong Zhang<sup>1,3,4</sup>, Hui Chen<sup>2</sup> and Xiuli Zuo<sup>1,3,4</sup>\*

<sup>1</sup>Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan, China, <sup>2</sup>Clinical Epidemiology Unit, Qilu Hospital of Shandong University, Jinan, China, <sup>3</sup>Shandong Provincial Clinical Research Center for Digestive Disease, Qilu Hospital of Shandong University, Jinan, China, <sup>4</sup>Laboratory of Translational Gastroenterology, Qilu Hospital of Shandong University, Jinan, China, <sup>5</sup>Department of Psychology, Qilu Hospital of Shandong University, Jinan, China

**Background:** The brain-gut axis link has attracted increasing attention, with observational studies suggesting that the relationship between common mental disorders and inflammatory bowel disease (IBD) may run in both directions. However, so far, it is not clear whether there is causality and in which direction.

**Methods:** We conducted a bidirectional 2-sample Mendelian randomization study to investigate the relationship between IBD, including Crohn's disease (CD) and ulcerative colitis (UC), and mental disorders, using summary-level GWAS data. The main analysis was the inverse variance weighted method. IBD (including CD and UC), and nine mental disorders were used as both exposures and outcomes.

**Results:** We found that UC could significantly lead to obsessive-compulsive disorder, attention deficit hyperactivity disorder, and autism spectrum disorder, with odds ratio (OR) of 1.245 (95% confidence intervals [CI]: 1.069-1.450; P=0.008), 1.050 (95%CI: 1.023-1.077; P=2.42×10<sup>-4</sup>), and 1.041 (95%CI: 1.015-1.068; P=0.002) respectively. In addition, we found that bipolar disorder and schizophrenia could increase the odds of IBD, with OR values of 1.138 (95%CI: 1.084-1.194; P=1.9×10<sup>-7</sup>), and 1.115 (95%CI: 1.071-1.161; P=1.12×10<sup>-7</sup>), respectively. Our results also indicate that obsessive-compulsive disorder could lead to IBD, especially for UC, with OR values of 1.091 (95%CI: 1.024-1.162; P=0.009), and 1.124 (95%CI: 1.041-1.214; P=0.004), respectively.

**Conclusions:** Our findings indicate that the brain-gut axis involves the association between IBD, especially UC, and some mental disorders, which guides the targeted prevention, management, and mechanism exploration of these diseases.

#### KEYWORDS

mental disorders, Crohn's disease, ulcerative colitis, inflammatory bowel disease, Mendelian randomization (MR)

# 1 Introduction

Inflammatory bowel disease (IBD), containing Crohn's disease (CD) and ulcerative colitis (UC), is a chronic systemic immunemediated inflammatory disease that mainly affects the digestive system (1). The predominant clinical symptoms of IBD are abdominal pain and diarrhea. For UC patients, anal bleeding is also a common symptom (2). In UC, inflammation is limited to colon mucosa and rectal mucosa, but in CD, inflammation involves any transmural segment of the entire digestive tract from mouth to anus (3). IBD often occurs in early adulthood and is associated with subsequent colorectal cancer, stroke, and other diseases (3-6). IBD is widespread in Europe, North America, Oceania, and other regions with higher socio-economic status (5, 7). In Europe, one in 198 people is diagnosed with UC, and one in 310 people is diagnosed with CD. In the past three decades, the incidence rate of newly industrialized countries and territories in Asia, South America, and Africa has been rising (8). The huge disease burden makes the exploration of prevention and treatment measures for IBD a top priority.

Mental disorders are a kind of chronic diseases, mainly including attention deficit hyperactivity disorder (ADHD), anxiety disorder, autism spectrum disorder (ASD), bipolar disorder (BD), anorexia nervosa (AN), major depressive disorder (MDD), obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), etc (9). The burden of diseases caused by mental disorders is heavy. In the past three decades, the number of disability-adjusted life years (DALYs) caused by mental disorders has climbed from 80.8 million to 125.3 million (9). During COVID-19, the disease burden of mental disorders may further increase (10). Some previous articles have suggested that IBD and mental disorders keep intimate bi-directional links with each other (11). Kuan-Yi Sung et al. explored the relationship between schizophrenia and IBD using the Taiwan National Health Insurance Research Database and reported that there was a significant correlation between schizophrenia and the subsequent development of IBD (12). Charles N Bernstein et al. used population-based administrative health data from Manitoba, Canada finding that the incidence rate and prevalence of mental disorders ascended in the IBD population (13). Daniele Ferrarese et al. observed a high prevalence rate of PTSD and dissociative symptoms among IBD patients (14). Maunoo Lee et al. reported that children with autism spectrum disorders have a higher prevalence rate of IBD using the data from the Military Health System database (15). Nosheen Umar et al. found that intentional self-harm, anxiety, depression, and insomnia were more likely to occur in IBD patients using the retrospective UK primary care medical database (16). However, the current studies are mostly limited to the observational correlation, and the cause and effect between IBD and mental disorders are still unknown.

The Mendelian randomization (MR) method is a common approach in causality research, which is similar to randomized controlled trials and is a natural randomized trial (17–21). The application of the MR method has three basic prerequisites: (a) instrumental variables, namely gene polymorphism, are closely related to exposure factors; (b) instrumental variables should be independent of any exposure confounders; (c) the association between instrumental variables and research outcomes only exists through exposure factors. Along with the rapid progress of sequencing technology, abundant large-scale genome-wide association studies (GWAS) data on mental disorders and IBD have been publicly reported. This provides an opportunity to use the MR method to explore and assess the bi-directional causal relationship between mental disorders and IBD based on summarylevel data. In the current study, we applied a two-sample MR (2SMR) approach to evaluate the bi-directional causal relationship between nine mental disorders and IBD, (including UC and CD subtypes), in order to provide evidence for the prevention and control of the corresponding diseases.

# 2 Methods

### 2.1 Ethics considerations

This current study is based on the summary results from the published studies. Ethical approval for each of the included studies can be found in the original publication. Because our study uses summary-level data and ethical approval and informed consent were obtained in all original studies, ethical approval is exempted in our hospital.

## 2.2 Study design

To explore and assess the association between IBD and nine mental disorders, we performed a 2SMR analysis based on summarylevel GWAS, which followed the Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization (STROBE-MR) checklist (Supplementary checklist). The core principle of the MR method and the three prerequisites of instrumental variables in our study, namely, the relevance assumption, independence assumption, and exclusion-restriction assumption, were summarized in Figure 1A. The flow chart of our 2SMR analysis in this study was summarized in Figure 1B.

## 2.3 Data sources

GWAS data of IBD, containing CD and UC, came from European GWAS, which was structured based on up to 15 original studies on European populations. 12882 IBD cases (21770 healthy controls), 5956 CD cases (14927 healthy controls), and 6968 UC cases (20464 healthy controls) were available in this data set, with corresponding GWAS IDs of ieu-a-31, ieu-a-30, and ieu-a-32, respectively (25). GWAS data for mental disorders is from ANGST Consortium, IOCDF-GC & OCGAS, and Psychiatric Genomics Consortium (PGC, https://pgc.unc.edu). According to DSM-5, we included most mental disorders, including ADHD, anxiety disorder, ASD, BD, AN, MDD, OCD, PTSD, and



Schematic overview of this 2SMR study design. (A) Principles of this 2SMR study. Three principal assumptions in MR design, as follows: (I) The relevance assumption—the selected instrument is a prediction of the exposure; (II) The independence assumption—the instrument is independent o any confounders of the exposure and outcome; and (III) The exclusion-restriction assumption—the instrument is only associated with the outcome through the exposure. (B) The research design and framework of our study [International Obsessive Compulsive Disorder Foundation Genetics Collaborative (IOCDF-GC) and OCD Collaborative Genetics Association Studies (OCGAS) (22); Demontis et al. (23); Grove et al. (24); Liu et al. (25); Mullins et al. (26); Nievergelt et al. (27); Otowa et al. (28); Trubetskoy et al. (29); Watson et al. (30); Wray et al. (31)].

schizophrenia (9). 19099 ADHD cases (34194 controls), 18382 ASD cases (27969 controls), 41917 BD cases (371549 controls), 16992 AN cases (55525 controls), 59851 MDD cases (113154 controls), 23212 PTSD cases (151447 controls), and 52017 schizophrenia cases (75889 controls) were available in PGC data set (23, 24, 26, 27, 29–31), 5712 anxiety disorder cases (11598 controls) were available in ANGST Consortium data set (28) and 2688 OCD cases (7037 controls) were available in IOCDF-GC & OCGAS

data set (22). The summary information of these GWAS studies could be found in Table 1.

# 2.4 Instruments selection

The genetic instrumental variables of gastrointestinal disorders, namely the determined single nucleotide polymorphisms (SNPs) of

Trait (reference)	Ancestry	Sample size	Cases	Controls	Number of SNPs	<i>P-</i> value	No. SNPs in MR	LD	F-statis- tic range	R2, %	PMID
Gastrointestinal	disorders					1					
Inflammatory bowel disease (25)	Only Europeans	34652	12882	21770	12716084	5E-08	79	0.001	29.81- 290.21	13.66	26192919
Crohn's disease (25)	Only Europeans	20883	5956	14927	12276506	5E-08	63	0.001	29.97- 272.94	17.88	26192919
Ulcerative colitis (25)	Only Europeans	27432	6968	20464	12255197	5E-08	48	0.001	29.71- 226.24	11.36	26192919
Mental disorder	'S										
ADHD (23)	Only Europeans	53293	19099	34194	8094094	0.00005	184	0.001	16.44-50.71	7.25	30478444
Anxiety disorder ( <mark>28</mark> )	Only Europeans	17310	5712	11598	6330995	0.00005	86	0.001	16.45-31.94	16.74	26754954
ASD (24)	Only Europeans	46351	18382	27969	9112386	0.00005	147	0.001	16.44-35.77	6.02	30804558
BD (26)	Only Europeans	413466	41917	371549	7608183	0.00005	383	0.001	16.47-79.65	2.16	34002096
AN (30)	Only Europeans	72517	16992	55525	8219102	0.00005	191	0.001	16.44-60.70	5.16	31308545
MDD (31)	Only Europeans	173005	59851	113154	13554550	0.00005	149	0.001	16.37-44.50	1.71	29700475
OCD (22)	>85% Europeans	9725	2688	7037	8409516	0.00005	103	0.001	16.47-25.57	19.75	28761083
PTSD (27)	≥90% Europeans	174659	23212	151447	9766174	0.00005	137	0.001	16.48-35.03	1.45	31594949
Schizophrenia (29)	Only Europeans	127906	52017	75889	7659767	0.00005	536	0.001	16.38- 175.28	11.77	35396580

TABLE 1	The summary of instrumenta	l variables for gastrointestinal dis	sorders ( $P < 5 \times 10^{-8}$ ) and mental disord	ers ( $P < 5 \times 10^{-5}$ ).

SNPs, single nucleotide polymorphisms; MR, Mendelian randomization; LD, linkage disequilibrium; PMID, PubMed Unique Identifier; ADHD, attention deficit hyperactivity disorder; ASD, autism spectrum disorder; BD, bipolar disorder; AN, anorexia nervosa; MDD, major depressive disorder; OCD, obsessive-compulsive disorder; PTSD, post-traumatic stress disorder.

IBD, CD, and UC were identified in the above-mentioned European GWAS with the following condition of  $P < 5 \times 10^{-8}$ , and linkage disequilibrium (LD):  $r^2 = 0.001$  and clump distance = 10,000 kb. 79 independent SNPs related to IBD disorders were finally gained on 34652 individuals of European ancestry. In addition, 63 independent SNPs related to CD were selected from 20833 individuals of European ancestry, and 48 independent SNPs related to UC were identified from 27432 European participants (25).

The genetic instrumental variables of mental disorders, namely the determined SNPs of ADHD, anxiety disorder, ASD, BD, AN, MDD, OCD, PTSD, and schizophrenia were identified in PGC, IOCDF-GC & OCGAS and ANGST Consortium with the following conditions of  $P < 5 \times 10^{-5}$ , and LD:  $r^2 = 0.001$  and clump distance = 10,000 kb. 184 independent SNPs for ADHD (n = 53293), 147 SNPs for ASD (n = 46351), 383 SNPs for BD (n = 413466), 191 SNPs for AN (n = 72517), 149 SNPs for MDD (n = 173005), 137 SNPs for PTSD (n = 174659), and 536 SNPs for schizophrenia (n = 127906) were obtained from European ancestry in PGC data set (23, 24, 26, 27, 29–31). A total of 86 independent SNPs related to anxiety disorder were extracted from 17310 individuals of European ancestry in the ANGST Consortium (28), and 103 independent SNPs for OCD were identified from 9725 individuals (>85% European) in IOCDF-GC & OCGAS (22). Depending on the PhennoScanner database (http://www.phenoscanner.medschl.cam.ac.uk/, accessed on 6 March 2023), the SNPs that do not achieve the whole genome significance level with confounding factors are retained in the genetic instrument (32). The variance  $(R^2)$  in the MR study can represent the proportion of total exposure difference explained by the potential instrumental variables. The R<sup>2</sup> of instrumental variables for IBD and mental disorders can be obtained from the original studies or calculated by the formula listed below according to the summary statistical data of each exposure:  $R^2 = (2 * EAF * (1 - EAF) * Beta^2)/[(2 * EAF * (1 - EAF) * (1 - EAF) * Beta^2)/[(2 * EAF * (1 - EAF) * Beta$ EAF) \* Beta<sup>2</sup>) + (2 \* EAF \* (1 - EAF) \* N \* SE<sup>2</sup>)]. EAF denotes the effect of allele frequency, beta denotes the estimated genetic effect of SNP on each exposure factor, N denotes the sample size of GWAS and SE denotes the standard error of the estimated effect. We further calculated the F-statistic for each SNP by the formula listed below: Beta<sup>2</sup>/SE<sup>2</sup>. We retained the SNPs with F-statistics of more than 10 as the final genetic variables to avoid the risk of selecting weak instrumental variables. The priori statistical power was calculated using the mRnd power calculation online tool (33).

## 2.5 Statistical analyses

The existence of potential pleiotropy was evaluated by using the MR-Egger intercept test. If significant horizontal pleiotropy was observed, the MR-Egger regression was finally adopted, otherwise, the inverse-variance weighted (IVW) method was adopted. The heterogeneity was quantified by I<sup>2</sup> statistic and the P-value of Cochran's Q-statistics test. If significant heterogeneity was observed, the random-effect IVW model was adopted, otherwise, the fixed-effect IVW model was adopted. Furthermore, the sensitivity analyses were executed to verify the robustness of our research results. The application of MR-Egger regression, likelihood-based MR, weighted median method, penalized weighted median method, and MR Pleiotropy RESidual Sum and Outlier (MR-PRESSO) supports expounding and verifying causal relationships (34). In order to initially control the risk of potential multiple tests in our study, the P < 0.01 was a significant correlation, and P values between 0.01 and 0.05 were considered suggestive correlation. We used R software (Version 4.1.0; https://www.rproject.org/) to perform all statistical analyses and graph presentations. The R-based "TwoSampleMR" package was applied to conduct our MR analysis.

# **3** Results

### 3.1 Assessment of genetic instruments

Table 1 shows the GWAS summary information on the included gastrointestinal disorders and mental disorders. The variance explicated by the selected genetic instruments ranged from 11.36% to 17.88% for gastrointestinal disorders (all F statistics>10) and from 1.45% to 19.75% for mental disorders (all F statistics> 10). When priori the odds ratio (OR) of correlation strength was 1.2 (0.8) or stronger, some only at 1.1 (0.9), there was sufficient statistical power to detect significant differences (Supplementary Tables S1, S2). The original data information for the effective evaluation of the selected SNP associated with gastrointestinal disorders and mental disorders is given in the supplementary materials.

# 3.2 Causal atlas of gastrointestinal disorders on mental disorders

Figure 2 manifests the primary results of the causal relationship of gastrointestinal disorders with mental disorders. The MR Egger intercept test did not observe a significant pleiotropy, except for the causal relationship of CD on ADHD, and the causal relationship of UC on OCD. In the main results, we found a significant correlation between UC and odds of ADHD, ASD and OCD, with corresponding OR values of 1.050 (95% CI: 1.023-1.077;  $P=2.42\times10^{-4}$ ), 1.041 (95% CI: 1.015-1.068; P=0.002), 1.245 (95% CI: 1.069-1.450; P=0.008), respectively. In addition, we found a suggestive association that genetically determined CD could increase the odds of ADHD, UC could increase the odds of anxiety disorder, and IBD could increase the odds of PTSD, with corresponding OR values of 1.065 (95% CI: 1.001-1.133; P=0.046), 1.056 (95% CI: 1.000-1.115; P=0.048) and 1.026 (95% CI: 1.001-1.052; P=0.043), respectively.

# 3.3 Causal atlas of mental disorders on gastrointestinal disorders

Figure 3 manifests the main results of the MR estimation for the causal atlas of mental disorders on gastrointestinal disorders. The MR Egger intercept test identified a notable horizontal pleiotropy between ASD and IBD, ASD and CD, OCD and IBD, OCD and UC, and Schizophrenia and CD. We found that BD was significantly correlated with IBD, CD and UC, with OR values of 1.138 (95% CI: 1.084-1.194; P=1.9×10<sup>-7</sup>), 1.158 (95% CI: 1.094-1.225; P=3.62×10<sup>-7</sup>) and 1.137 (95% CI: 1.079-1.198; P=1.4×10<sup>-6</sup>), respectively. OCD was significantly correlated with IBD and UC, with OR values of 1.091 (95% CI: 1.024-1.162; P=0.009), and 1.124 (95% CI: 1.041-1.214; P=0.004), respectively. There was also a significant relevance between schizophrenia and IBD, CD and UC, with OR values of 1.115 (95% CI: 1.071-1.161; P=1.12×10<sup>-7</sup>), 1.098 (95% CI: 1.039-1.161; P=0.010) and 1.145 (95% CI: 1.096-1.195;  $P=8.4\times10^{-10}$ ), respectively. In addition, we found suggestive associations between ASD and CD, and MDD and UC, with OR values of 1.271 (95% CI: 1.040-1.554; P=0.021) and 1.113 (95% CI: 1.005-1.233; *P*=0.039), respectively.

## 3.4 Sensitivity analysis

We further developed a sensitivity analysis by selecting more stringent genetic instrumental variables for mental disorders ( $P < 5 \times 10^{-8}$ , LD: r2 = 0.001 and clump distance = 10,000 kb, Supplementary Table S3). Supplementary Table S4 pools the summary results via a variety of complementary MR methods of the causal atlas of gastrointestinal disorders on mental disorders. Complementary MR analyses further confirmed the suggestive association between UC and ADHD, UC and ASD, and UC and OCD. Supplementary Table S5 gathers the summary results via a variety of complementary MR methods of the causal atlas of mental disorders. Complementary MR methods of the causal atlas of software sensitive association between UC and ADHD, UC and ASD, and UC and OCD. Supplementary Table S5 gathers the summary results via a variety of complementary MR methods of the causal atlas of mental disorders on gastrointestinal disorders. Complementary MR analysis also confirmed the suggestive association between BD and gastrointestinal disorders, schizophrenia and gastrointestinal disorders. Our results did not alter fundamentally after leave-one-out analyses.

# 4 Discussion

In the current study, we conducted a comprehensive 2SMR study for the first time to explore the potential causal atlas between IBD and mental disorders. Genetic variation is used as an instrumental variable for mental disorders and IBD. Our research results show that UC and ADHD, UC and ASD, UC and OCD, BD

Exposure Outcome	Outroans N	No.SNPs Horizontal Pleiotropy test Heterogeneity test						100		OR (95%CI)	P-Value
	Outcome N	0.51115	MR-Egger	P-Value	Cochran's	Q I <sup>2</sup>	P-Value	MR method		OK (93%CI)	r-value
BD	ADHD	73	-0.002	0.796	85.677	0.160	0.129	IVW(fixed effects)		1.016(0.992,1.041)	0.194
CD	ADHD	57	-0.013	0.044	92.473	0.394	0.002	MR Egger	$\rightarrow$	1.065(1.001,1.133)	0.046
UC	ADHD	42	0.005	0.492	43.994	0.068	0.346	IVW(fixed effects)	<b>⊢</b> →	1.050(1.023,1.077)	2.42E-04
BD	Anxiety disord	er 72	0.006	0.600	54.923	-0.293	0.921	IVW(fixed effects)	<b>├</b> ── <b>→</b> ───┤	1.052(1.000,1.106)	0.051
CD	Anxiety disord	er 57	-0.004	0.749	45.315	-0.236	0.846	IVW(fixed effects)	<b>├</b> ── <b>↓</b>	1.009(0.967,1.053)	0.673
JC	Anxiety disord	er 42	-0.012	0.461	30.738	-0.334	0.879	IVW(fixed effects)	<b>├</b> ── <b>↓</b>	1.056(1.000,1.115)	0.048
BD	ASD	69	-0.005	0.481	96.236	0.293	0.014	IVW(random effects)	<b>⊢</b> →1	1.027(0.997,1.058)	0.076
CD	ASD	54	-0.010	0.130	70.750	0.251	0.052	IVW(fixed effects)	<b>⊢</b> ,	1.013(0.992,1.035)	0.214
UC	ASD	39	-0.001	0.950	45.203	0.159	0.196	IVW(fixed effects)	<b>⊢</b> →1	1.041(1.015,1.068)	0.002
BD	BD	62	0.005	0.417	116.234	0.475	2.62E-05	IVW(random effects)	<b>⊢♦</b> <u>+</u> 1	0.987(0.963,1.011)	0.289
CD	BD	51	-0.002	0.796	104.107	0.520	9.13E-05	IVW(random effects)	<b>⊢</b>	0.998(0.977,1.019)	0.845
JC	BD	35	0.005	0.480	60.549	0.438	0.003	IVW(random effects)	<b>⊢_</b> ♦	0.996(0.970,1.022)	0.735
BD	AN	65	-0.001	0.891	91.102	0.297	0.015	IVW(random effects)	⊢_♦	1.012(0.982,1.043)	0.435
CD	AN	53	-0.008	0.213	74.857	0.305	0.021	IVW(random effects)	<b>⊢</b> ,	1.012(0.988,1.038)	0.326
UC	AN	35	0.929	0.929	23.362	-0.455	0.915	IVW(fixed effects)	⊢+	1.011(0.982,1.041)	0.458
BD	MDD	62	0.003	0.397	66.848	0.087	0.283	IVW(fixed effects)	⊢♠┥	0.993(0.978,1.007)	0.332
CD	MDD	52	0.003	0.457	68.929	0.260	0.048	IVW(random effects)	<b>⊢</b> •−I	0.997(0.983,1.011)	0.668
UC	MDD	36	0.005	0.263	48.957	0.285	0.059	IVW(fixed effects)	⊢◆⊣	1.007(0.992,1.022)	0.385
IBD	OCD	70	0.001	0.977	81.840	0.157	0.138	IVW(fixed effects)	<b>→</b>	1.009(0.951,1.071)	0.767
CD	OCD	55	0.006	0.654	60.768	0.111	0.245	IVW(fixed effects)	<b>⊢ → − − −</b>	1.021(0.972,1.073)	0.410
UC	OCD	41	-0.043	0.011	46.484	0.139	0.223	MR Egger	$\longrightarrow$	1.245(1.069,1.450)	0.008
BD	PTSD	78	0.001	0.928	83.341	0.076	0.291	IVW(fixed effects)	<b>⊢</b>	1.026(1.001,1.052)	0.043
CD	PTSD	62	-0.005	0.425	77.637	0.214	0.074	IVW(fixed effects)	<b>⊢♦</b> −1	1.020(0.999,1.042)	0.062
UC	PTSD	46	0.001	0.942	48.059	0.064	0.350	IVW(fixed effects)	┝━━━┥	1.026(0.999,1.052)	0.055
BD	Schizophrenia	62	-0.004	0.428	122.655	0.503	4.92E-06	IVW(random effects)	⊢+	1.016(0.990,1.043)	0.233
CD	Schizophrenia	51	0.005	0.476	184.654	0.729	2.55E-17	IVW(random effects)	<b>⊢</b> ,	1.021(0.995,1.047)	0.110
UC	Schizophrenia	35	-0.004	0.619	67.623	0.497	0.001	IVW(random effects)	<b>⊢♦</b> −−1	1.005(0.979,1.030)	0.723

FIGURE 2

The primary results of the causal atlas of gastrointestinal disorders on mental disorders. ADHD, attention deficit hyperactivity disorder; ASD, autism spectrum disorder; BD, bipolar disorder; AN, anorexia nervosa; MDD, major depressive disorder; OCD, obsessive-compulsive disorder; PTSD, post-

traumatic stress disorder; IBD, inflammatory bowel disease; CD, Crohn's disease; UC, ulcerative colitis.

and IBD, OCD and UC, schizophrenia and IBD are significantly related, and there may be potential causal associations. In addition, we also discover some suggestive associations suggesting that CD can increase the odds of ADHD, UC is related to the increased anxiety risk, IBD can promote the occurrence of PTSD, ASD is associated with increased CD risk, and MDD is associated with increased UC risk. The robust causal atlas between IBD and mental disorders was supported by multi-aspect sensitivity analyses.

Mu-Hong Chen et al. used the database from the Taiwan National Health Insurance Research System finding that the probability of UC in ADHD patients is 2.31 times greater than that in non-patients (35). Tor-Arne Hegwik et al. used cross-sectional study data based on 2.5 million people to plumb the relationship between ADHD and immune system diseases and found that ADHD was related to UC and CD, with OR values of 1.28 and 1.44 for females, while in males, ADHD was negatively related to CD (36). However, these studies only provided evidence of the association between ADHD and IBD and did not analyze its causal relationship. In our study, we found a potential causal relationship between UC and the occurrence of ADHD, and the incidence risk of ADHD in UC patients was 1.050 times greater

than in non-UC patients. In terms of ASD and OCD, we found that the risk of ASD and OCD in UC patients was 1.041 and 1.245 times higher than that in non-UC patients, respectively. Jong Yeob Kim et al. found that there was a correlation between ASD and the later development of IBD. The OR values between ASD and IBD, UC, CD of 1.66, 1.91, and 1.47, respectively, further support the results of Kim's study (37). In another study, the prevalence of OCD in IBD patients was significantly higher than that in the general healthy population, which was 9.4% and 2% respectively (38). Previous studies have shown that parents with IBD, especially mothers with IBD, are associated with subsequent ASD in children (39). This suggests that the two diseases may share a conjoint genetic basis and common risk factors (40). In addition, the brain-gut axis is also an attractive potential factor, involving complex interactions between neuroendocrine regulatory pathways, the central, peripheral, and autonomic nervous systems, as well as the gastrointestinal tract system (41). Previous studies have pointed out that intestinal inflammation may affect the activity and behavior of the brain by affecting key brain neurotransmitters, such as glutamate, TNF- $\alpha$ , etc. (42). In addition, along with changes in the intestinal microbial environment, the imbalances in the vagus nerve, immune-

Exposure Outco	tcome	H No.SNPs —	orizontal Pl	eiotropy tes	Heterogeneity test			MR method		OR (95%CI)	P-Value
	uome	INO.SINFS	MR-Egger	P-Value	Cochran's	Q I <sup>2</sup>	P-Value	MR method		OR (9370CI)	r-value
ADHD	IBD	169	-0.007	0.282	206.162	0.185	0.024	IVW(fixed effects)	<b>⊢</b> ●	1.038(0.996,1.081)	0.077
ADHD	CD	169	-0.013	0.351	127.976	0.351	0.001	IVW(random effects)	<b>⊢ ♦ −  </b>	1.029(0.973,1.088)	0.313
ADHD	UC	169	-0.007	0.379	203.273	0.174	0.033	IVW(fixed effects)	⊢_●	1.032(0.980,1.087)	0.229
Anxiety disord	ler IBD	82	-0.002	0.719	89.516	0.095	0.242	IVW(fixed effects)	⊢.	0.993(0.968,1.019)	0.599
Anxiety disord	er CD	82	-0.001	0.932	99.219	0.184	0.083	IVW(fixed effects)	<b>⊢↓</b>	0.973(0.939,1.007)	0.115
Anxiety disord	ler UC	82	-0.002	0.805	109.102	0.258	0.02	IVW(random effects)	<b>⊢♦</b> −1	1.006(0.969,1.044)	0.757
ASD	IBD	124	-0.013	0.035	146.082	0.158	0.076	MR Egger		1.157(1.000,1.338)	0.052
ASD	CD	124	-0.021	0.017	151.167	0.186	0.043	MR Egger	$\longrightarrow$	1.271(1.040,1.554)	0.021
ASD	UC	124	-0.012	0.144	148.9	0.174	0.056	IVW(fixed effects)	<b>⊢</b> →	0.990(0.931,1.052)	0.741
BD	IBD	317	-0.005	0.252	434.076	0.272	1.12E-05	IVW(random effects)	<b>⊢</b> →	1.138(1.084,1.194)	1.9E-07
BD	CD	317	-0.008	0.199	416.138	0.241	1.30E-04	IVW(fixed effects)	<b>⊢</b> →	1.158(1.094,1.225)	3.62E-07
BD	UC	317	-0.005	0.384	389.907	0.190	0.003	IVW(fixed effects)	<b>⊢_</b>	1.137(1.079,1.198)	1.4E-06
AN	IBD	152	-0.005	0.432	188.876	0.201	0.02	IVW(fixed effects)	<b>⊢</b> ←−1	1.039(0.995,1.085)	0.082
AN	CD	152	-0.001	0.943	166.478	0.093	0.184	IVW(fixed effects)	<b>⊢</b>	1.055(0.994,1.119)	0.076
AN	UC	152	-0.008	0.306	168.694	0.105	0.154	IVW(fixed effects)	<b>⊢♦</b> −−1	1.020(0.966,1.077)	0.476
MDD	IBD	125	0.007	0.179	132.897	0.067	0.276	IVW(fixed effects)		1.074(0.991,1.165)	0.084
MDD	CD	125	0.009	0.155	125.088	0.009	0.456	IVW(fixed effects)	<b>⊢ → − − − −</b>	1.059(0.948,1.183)	0.312
MDD	UC	125	0.004	0.504	128.929	0.038	0.363	IVW(fixed effects)	<b>⊢</b> →	1.113(1.005,1.233)	0.039
OCD	IBD	89	-0.016	0.018	98.32	0.105	0.212	MR Egger	⊢	1.091(1.024,1.162)	0.009
OCD	CD	89	-0.005	0.656	117.394	0.250	0.02	IVW(random effects)	<b>⊢↓</b>	1.002(0.965,1.040)	0.927
OCD	UC	89	-0.020	0.018	88.517	0.006	0.464	MR Egger	<b>⊢</b>	1.124(1.041,1.214)	0.004
PTSD	IBD	115	0.004	0.545	138.359	0.176	0.06	IVW(fixed effects)	<b>⊢</b> → <b>−</b> −1	0.989(0.941,1.041)	0.680
PTSD	CD	115	-0.005	0.599	123.247	0.075	0.261	IVW(fixed effects)	<b>⊢</b>	1.006(0.939,1.078)	0.862
PTSD	UC	115	0.005	0.514	133.349	0.145	0.104	IVW(fixed effects)	<b>⊢</b>	1.002(0.941,1.067)	0.951
Schizophrenia	IBD	442	-0.005	0.233	610.118	0.277	1.55E-07	IVW(random effects)		1.115(1.071,1.161)	1.12E-07
Schizophrenia	CD	442	-0.009	0.092	623.914	0.293	2.01E-08	MR Egger	$\longrightarrow$	1.286(1.062,1.559)	0.010
Schizophrenia	UC	442	-0.004	0.437	508.623	0.133	0.014	IVW(fixed effects)	<b>⊢</b>	1.145(1.096,1.195)	8.4E-10

FIGURE 3

The primary results of the MR estimates for the causal atlas of mental disorders on gastrointestinal disorders. ADHD, attention deficit hyperactivity disorder; ASD, autism spectrum disorder; BD, bipolar disorder; AN, anorexia nervosa; MDD, major depressive disorder; OCD, obsessive-compulsive disorder; PTSD, post-traumatic stress disorder; IBD, inflammatory bowel disease; CD, Crohn's disease; UC, ulcerative colitis.

inflammatory process and bacterial metabolites and products are related to the changes in blood-brain barrier function and neuroinflammation, which promotes the occurrence of mental disorders (43, 44).

Several previous researches have suggested that there is a close correlation between IBD and BD. Li-Ting Kao et al. used the database from the National Health Insurance Research system to report a significant cross-sectional association between IBD and BD with an OR of 2.10 (45). Charles N Bernstein et al. used populationbased administrative health data from Manitoba, Canada data finding that the incidence rate of BD in IBD patients is 1.84 times higher. Females, with higher socio-economic status, 18-24 years old may be a risk factor (13). However, the authentic causal relationship between IBD and BD is still unknown. In this study, we revealed the potential causal relationship between BD and IBD, CD, and UC from the perspective of genetic linkage. The risk of IBD, CD, and UC in patients with BD was 1.138, 1.158, and 1.137 times higher than that in patients without BD, respectively. Zhe Wang et al. used the 2SMR method to inquire into the causal relationship of IBD with BD. The results stated that the predicted hereditary BD has a significant and positive correlation with the risk of IBD, CD, and

UC, with ORs of 1.16, 1.20, and 1.17 respectively, which were consistent with our results (46). We also found a significant correlation between schizophrenia and IBD, CD, and UC, with OR values of 1.115, 1.098, and 1.145, respectively. Previous studies have reported that the incidence of schizophrenia in IBD patients is 1.64 times higher than that in the control population, which indicates the correlation between the two and supports this study to some extent (13). Mental disorders may promote the occurrence of IBD through the brain-gut axis, involving the vegetative nervous system, central nervous system responses, stress pathways response (hypothalamus-pituitary-adrenal axis), (gastrointestinal) corticotropin-releasing factor pathways, etc (47, 48). Emotional changes may also increase intestinal permeability so that intestinal bacteria can transfer to peripheral lymphatic organs through the intestinal tract, trigger an innate immune response, and promote the development of IBD (42). In addition, the abundance of gut microbiota is also a potential cause. A study on the gut microbiome of patients with depression has found that depression is associated with a decrease in gut microbiome richness and diversity, suggesting that this may be a potential influencing factor (49, 50).

Previous documents have implied that there is a two-way relationship between anxiety and depression and IBD (51). However, in this study, we only found a suggestive association that UC slightly increases the risk of anxiety, while MDD is significantly associated with an increased risk of UC. In addition, we found suggestive association that IBD is associated with an incremented incidence of PTSD, and ASD is associated with increased CD risk. Considering that the criteria we used when screening the tool variables of mental disorders are  $P < 5 \times 10^{-5}$ , LD:  $r^2 = 0.001$ , and clump distance = 10,000 kb, this part of the results needs to be further verified with GWAS data of a larger sample.

Our study has some specific benefits. To begin with, our study applied the instrumental variable-based 2SMR design to reduce the impacts of uncontrolled confounding factors and small sample selection bias, and to replenish the genetically theoretical cornerstone of the bi-directional causal atlas between various mental disorders and IBD. Furthermore, our study comprehensively analyzed the causal relationship between nine mental disorders and IBD with its subtypes from two directions in detail, which is the most integrated study based on the 2SMR method at present. Finally, our research carried out multifaceted sensitivity analyses, and the outcomes gained by other approaches were accordant with the main IVW methods, which further demonstrated the robustness of our findings.

The main limitations of our study have been stated below. First, the statistical analysis of this study is dependent on the published summary data rather than personal data information. Consequently, we cannot examine the possible nonlinear causal relationship between mental disorders and IBD. In addition, we cannot evaluate the causal atlas between mental disorders and IBD by gender. Second, the congenital shortage of the MR analysis method is that the potential pleiotropy can affect the accuracy of causal inference. Fortunately, no SNP remarkably related to confounding was identified via the PhennoScanner database, and the MR Egger intercept test in our study presented that there was almost no notable pleiotropic effect, which proclaims that the pleiotropic effect was unlikely to occur for most causal estimations. For a small amount of significant horizontal pleiotropy, the MR-Egger regression was used to further adjust the causal association. Third, albeit we have only observed significant associations in UC and ADHD, UC and ASD, UC and OCD, BD and IBD, schizophrenia and IBD, we cannot utterly eliminate the possibility that the influence of mental system diseases and IBD is too small to be determined. These weak relationships may be discovered through the subsequent use of large-scale data. Fourth, because there are fewer reliable instrument variables available for the mental disorders of interest, in order to include more potentially available tool variables, we use  $P < 5 \times 10^{-5}$  as one of the screening conditions for instrument variables, which makes the ability to detect the suggestive effect of mental disorders on IBD may be relatively low in this study. This may also lead to some relationships being difficult to discover in this study, therefore, more large-scale GWAS samples on exposure need to be used to verify our results in the future.

In this MR study, the results show that there is a significant causal relationship between UC and ADHD, UC and ASD, UC and OCD, BD and IBD, OCD and UC, and schizophrenia and IBD. In addition, we also found some suggestive associations that CD can increase the odds of ADHD, UC is related to the increased anxiety risk, IBD can promote the occurrence of PTSD, ASD is associated with increased CD risk, and MDD is associated with increased UC risk. The findings of our study further emphasize the interaction between the brain-gut axis from a genetic perspective, and improve the understanding of the causal atlas between IBD and various mental illnesses for clinicians and primary care doctors, which will help to make an accurate comprehensive diagnosis and interdisciplinary joint treatment care for potential patients in a more timely manner. In the future, more mechanism exploration and treatment interventions on mental disorders and IBD could be conducted to verify and extend our results and bring potential clinical benefits.

# Data availability statement

The original data sources used to support our findings of this study are provided within the supplementary material (Supplementary Tables S6-S59). All summary statistics approaches for the two-sample Mendelian randomization are retrieved online from every genome-wide association study consortia. Further inquiries can be directed to the corresponding authors.

# Author contributions

XY: Conceptualization, Data curation, Formal Analysis, Funding acquisition, Methodology, Visualization, Writing – original draft, Writing – review & editing. LY: Methodology, Supervision, Writing – review & editing. TZ: Data curation, Methodology, Validation, Visualization, Writing – review & editing. HZ: Software, Supervision, Visualization, Writing – review & editing. HC: Software, Supervision, Visualization, Writing – review & editing. XZ: Conceptualization, Funding acquisition, Methodology, Supervision, Writing – review & editing.

# Funding

The authors declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the National Natural Science Foundation of China (82270570 and 82103912), the China Postdoctoral Science Foundation (2021M700080), the Excellent Youth Innovation Team of Shandong Provincial Higher Education Institutions (2022KJ012), and Shandong Provincial Natural Science Foundation (ZR2020QH302). The funder had no role in the study design, data collection, data analysis, data interpretation, or preparation of the manuscript. All authors have full

access to the study data, and the corresponding author has the final responsibility of the decision to submit the manuscript for publication.

## Acknowledgments

The authors acknowledge the participants and investigators of the included GWAS studies.

# Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

# References

1. Freuer D, Linseisen J, Meisinger C. Association between inflammatory bowel disease and both psoriasis and psoriatic arthritis: A bidirectional 2-sample Mendelian randomization study. *JAMA Dermatol* (2022) 158:1262-8. doi: 10.1001/jamadermatol.2022.3682

2. Kobayashi T, Siegmund B, Le Berre C, Wei SC, Ferrante M, Shen B, et al. Ulcerative colitis. *Nat Rev Dis Primers* (2020) 6:74. doi: 10.1038/s41572-020-0205-x

3. Ferro JM, Oliveira Santos M. Neurology of inflammatory bowel disease. J Neurol Sci (2021) 424:117426. doi: 10.1016/j.jns.2021.117426

4. Nagao-Kitamoto H, Kitamoto S, Kamada N. Inflammatory bowel disease and carcinogenesis. *Cancer Metastasis Rev* (2022) 41:301–16. doi: 10.1007/s10555-022-10028-4

5. Wehkamp J, Götz M, Herrlinger K, Steurer W, Stange EF. Inflammatory bowel disease. *Dtsch Arztebl Int* (2016) 113:72–82. doi: 10.3238/arztebl.2016.0072

6. Mouratidou N, Malmborg P, Järås J, Sigurdsson V, Sandström O, Fagerberg UL, et al. Identification of childhood-onset inflammatory bowel disease in Swedish healthcare registers: A validation study. *Clin Epidemiol* (2022) 14:591–600. doi: 10.2147/CLEP.S358031

7. Ma T, Wan M, Liu G, Zuo X, Yang X, Yang X. Temporal trends of inflammatory bowel disease burden in China from 1990 to 2030 with comparisons to Japan, South Korea, the European Union, the United States of America, and the world. *Clin Epidemiol* (2023) 15:583–99. doi: 10.2147/CLEP.S402718

8. Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. *Lancet* (2017) 390:2769–78. doi: 10.1016/S0140-6736(17)32448-0

9. GBD 2019 Mental Disorders Collaborators. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet Psychiatry* (2022) 9:137–50. doi: 10.1016/S2215-0366(21)00395-3

10. Winkler P, Formanek T, Mlada K, Kagstrom A, Mohrova Z, Mohr P, et al. Increase in prevalence of current mental disorders in the context of COVID-19: analysis of repeated nationwide cross-sectional surveys. *Epidemiol Psychiatr Sci* (2020) 29:e173. doi: 10.1017/S2045796020000888

11. Hodson R. Inflammatory bowel disease. Nature (2016) 540:S97. doi: 10.1038/540S97a

12. Sung KY, Zhang B, Wang HE, Bai YM, Tsai SJ, Su TP, et al. Schizophrenia and risk of new-onset inflammatory bowel disease: a nationwide longitudinal study. *Aliment Pharmacol Ther* (2022) 55:1192–201. doi: 10.1111/apt.16856

13. Bernstein CN, Hitchon CA, Walld R, Bolton JM, Sareen J, Walker JR, et al. Increased burden of psychiatric disorders in inflammatory bowel disease. *Inflamm Bowel Dis* (2019) 25:360–8. doi: 10.1093/ibd/izy235

14. Ferrarese D, Spagnolo G, Vecchione M, Scaldaferri F, Armuzzi A, Chieffo D, et al. Signs of dissociation and symptoms of post-traumatic stress disorder in inflammatory bowel disease: A case-control study. *Dig Dis* (2022) 40:701–9. doi: 10.1159/000521424

15. Lee M, Krishnamurthy J, Susi A, Sullivan C, Gorman GH, Hisle-Gorman E, et al. Association of autism spectrum disorders and inflammatory bowel disease. J Autism Dev Disord (2018) 48:1523–9. doi: 10.1007/s10803-017-3409-5

16. Umar N, King D, Chandan JS, Bhala N, Nirantharakumar K, Adderley N, et al. The association between inflammatory bowel disease and mental ill health: a

# Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

# Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2023. 1267834/full#supplementary-material

retrospective cohort study using data from UK primary care. Aliment Pharmacol Ther (2022) 56:814-22. doi: 10.1111/apt.17110

17. Flatby HM, Ravi A, Damås JK, Solligård E, Rogne T. Circulating levels of micronutrients and risk of infections: a Mendelian randomization study. *BMC Med* (2023) 21:84. doi: 10.1186/s12916-023-02780-3

18. Ye D, Liu B, He Z, Huang L, Qian Y, Shao K, et al. Assessing the associations of growth differentiation factor 15 with rheumatic diseases using genetic data. *Clin Epidemiol* (2021) 13:245–52. doi: 10.2147/CLEP.S305024

19. Li P, Wang H, Guo L, Gou X, Chen G, Lin D, et al. Association between gut microbiota and preeclampsia-eclampsia: a two-sample Mendelian randomization study. *BMC Med* (2022) 20:443. doi: 10.1186/s12916-022-02657-x

20. Lv L, Sun X, Liu B, Song J, Wu DJH, Gao Y, et al. Genetically predicted serum albumin and risk of colorectal cancer: A bidirectional Mendelian randomization study. *Clin Epidemiol* (2022) 14:771–8. doi: 10.2147/CLEP.S367547

21. Lv X, Gao X, Liu J, Deng Y, Nie Q, Fan X, et al. Immune-mediated inflammatory diseases and risk of venous thromboembolism: A Mendelian randomization study. *Front Immunol* (2022) 13:1042751. doi: 10.3389/fimmu.2022.1042751

22. International Obsessive Compulsive Disorder Foundation Genetics Collaborative (IOCDF-GC) and OCD Collaborative Genetics Association Studies (OCGAS). Revealing the complex genetic architecture of obsessive-compulsive disorder using meta-analysis. *Mol Psychiatry* (2018) 23:1181–8. doi: 10.1038/mp.2017.154

23. Demontis D, Walters RK, Martin J, Mattheisen M, Als TD, Agerbo E, et al. Discovery of the first genome-wide significant risk loci for attention deficit/ hyperactivity disorder. *Nat Genet* (2019) 51:63–75. doi: 10.1038/s41588-018-0269-7

24. Grove J, Ripke S, Als TD, Mattheisen M, Walters RK, Won H, et al. Identification of common genetic risk variants for autism spectrum disorder. *Nat Genet* (2019) 51:431–44. doi: 10.1038/s41588-019-0344-8

25. Liu JZ, van Sommeren S, Huang H, Ng SC, Alberts R, Takahashi A, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. *Nat Genet* (2015) 47:979–86. doi: 10.1038/ng.3359

26. Mullins N, Forstner AJ, O'Connell KS, Coombes B, Coleman JRI, Qiao Z, et al. Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. *Nat Genet* (2021) 53:817–29. doi: 10.1038/s41588-021-00857-4

27. Nievergelt CM, Maihofer AX, Klengel T, Atkinson EG, Chen CY, Choi KW, et al. International meta-analysis of PTSD genome-wide association studies identifies sexand ancestry-specific genetic risk loci. *Nat Commun* (2019) 10:4558. doi: 10.1038/ s41467-019-12576-w

28. Otowa T, Hek K, Lee M, Byrne EM, Mirza SS, Nivard MG, et al. Meta-analysis of genome-wide association studies of anxiety disorders. *Mol Psychiatry* (2016) 21:1391–9. doi: 10.1038/mp.2015.197

29. Trubetskoy V, Pardiñas AF, Qi T, Panagiotaropoulou G, Awasthi S, Bigdeli TB, et al. Mapping genomic loci implicates genes and synaptic biology in schizophrenia. *Nature* (2022) 604:502–8. doi: 10.1038/s41586-022-04434-5

30. Watson HJ, Yilmaz Z, Thornton LM, Hübel C, Coleman JRI, Gaspar HA, et al. Genome-wide association study identifies eight risk loci and implicates metabopsychiatric origins for anorexia nervosa. *Nat Genet* (2019) 51:1207–14. doi: 10.1038/ s41588-019-0439-2 31. Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, Abdellaoui A, et al. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. *Nat Genet* (2018) 50:668–81. doi: 10.1038/s41588-018-0090-3

32. Kamat MA, Blackshaw JA, Young R, Surendran P, Burgess S, Danesh J, et al. PhenoScanner V2: an expanded tool for searching human genotype-phenotype associations. *Bioinformatics* (2019) 35:4851–3. doi: 10.1093/bioinformatics/btz469

33. Brion MJ, Shakhbazov K, Visscher PM. Calculating statistical power in Mendelian randomization studies. *Int J Epidemiol* (2013) 42:1497–501. doi: 10.1093/ ije/dyt179

34. Zhang X, Zhao H, Man J, Yin X, Zhang T, Yang X, et al. Investigating causal associations of diet-derived circulating antioxidants with the risk of digestive system cancers: A Mendelian randomization study. *Nutrients* (2022) 14. doi: 10.3390/nu14153237

35. Chen MH, Su TP, Chen YS, Hsu JW, Huang KL, Chang WH, et al. Comorbidity of allergic and autoimmune diseases among patients with ADHD. *J Atten Disord* (2017) 21:219–27. doi: 10.1177/1087054712474686

36. Hegvik TA, Instanes JT, Haavik J, Klungsøyr K, Engeland A. Associations between attention-deficit/hyperactivity disorder and autoimmune diseases are modified by sex: a population-based cross-sectional study. *Eur Child Adolesc Psychiatry* (2018) 27:663–75. doi: 10.1007/s00787-017-1056-1

37. Kim JY, Choi MJ, Ha S, Hwang J, Koyanagi A, Dragioti E, et al. Association between autism spectrum disorder and inflammatory bowel disease: A systematic review and meta-analysis. *Autism Res* (2022) 15:340–52. doi: 10.1002/aur.2656

38. Neuendorf R, Harding A, Stello N, Hanes D, Wahbeh H. Depression and anxiety in patients with Inflammatory Bowel Disease: A systematic review. *J Psychosom Res* (2016) 87:70–80. doi: 10.1016/j.jpsychores.2016.06.001

39. Sadik A, Dardani C, Pagoni P, Havdahl A, Stergiakouli E, Khandaker GM, et al. Parental inflammatory bowel disease and autism in children. *Nat Med* (2022) 28:1406–11. doi: 10.1038/s41591-022-01845-9

40. Gong W, Guo P, Li Y, Liu L, Yan R, Liu S, et al. Role of the gut-brain axis in the shared genetic etiology between gastrointestinal tract diseases and psychiatric disorders: A genome-wide pleiotropic analysis. *JAMA Psychiatry* (2023) 80:360–70. doi: 10.1001/jamapsychiatry.2022.4974

41. Gracie DJ, Hamlin PJ, Ford AC. The influence of the brain-gut axis in inflammatory bowel disease and possible implications for treatment. *Lancet Gastroenterol Hepatol* (2019) 4:632–42. doi: 10.1016/S2468-1253(19)30089-5

42. Peppas S, Pansieri C, Piovani D, Danese S, Peyrin-Biroulet L, Tsantes AG, et al. The brain-gut axis: psychological functioning and inflammatory bowel diseases. *J Clin Med* (2021) 10. doi: 10.3390/jcm10030377

43. Rutsch A, Kantsjö JB, Ronchi F. The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology. *Front Immunol* (2020) 11:604179. doi: 10.3389/fimmu.2020.604179

44. Long-Smith C, O'Riordan KJ, Clarke G, Stanton C, Dinan TG, Cryan JF. Microbiota-gut-brain axis: new therapeutic opportunities. *Annu Rev Pharmacol Toxicol* (2020) 60:477–502. doi: 10.1146/annurev-pharmtox-010919-023628

45. Kao LT, Lin HC, Lee HC. Inflammatory bowel disease and bipolar disorder: A population-based cross-sectional study. *J Affect Disord* (2019) 247:120–4. doi: 10.1016/j.jad.2019.01.014

46. Wang Z, Wang X, Zhao X, Hu Z, Sun D, Wu D, et al. Causal relationship between bipolar disorder and inflammatory bowel disease: A bidirectional two-sample mendelian randomization study. *Front Genet* (2022) 13:970933. doi: 10.3389/ fgene.2022.970933

47. Osadchiy V, Martin CR, Mayer EA. The gut-brain axis and the microbiome: mechanisms and clinical implications. *Clin Gastroenterol Hepatol* (2019) 17:322–32. doi: 10.1016/j.cgh.2018.10.002

48. Balsiger LM, Carbone F, Raymenants K, Scarpellini E, Tack J. Understanding and managing patients with overlapping disorders of gut-brain interaction. *Lancet Gastroenterol Hepatol* (2023) 8:383–90. doi: 10.1016/S2468-1253(22)00435-6

49. Limbana T, Khan F, Eskander N. Gut microbiome and depression: how microbes affect the way we think. *Cureus* (2020) 12:e9966. doi: 10.7759/cureus.9966

50. Zheng P, Zeng B, Zhou C, Liu M, Fang Z, Xu X, et al. Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host's metabolism. *Mol Psychiatry* (2016) 21:786–96. doi: 10.1038/mp.2016.44

51. Fairbrass KM, Lovatt J, Barberio B, Yuan Y, Gracie DJ, Ford AC. Bidirectional brain-gut axis effects influence mood and prognosis in IBD: a systematic review and meta-analysis. *Gut* (2022) 71:1773–80. doi: 10.1136/gutjnl-2021-325985